ABL1 and leukemia: As PMIBcr/Abl‐R6 targets Bcr/Abl oligomerization instead of the Abl kinase domain, it will be able to overcome Ph+ leukemia TKI resistance due to Abl mutations, and its multiple mechanisms of cancer cell killing will allow us to reverse drug resistance that is independent of Abl mutations.